The Scientist5mon
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex ® Biopark in Visp (CH). In addition, ...
pharmaphorum1y
Lonza builds its ADC capacity with Synaffix takeover
Lonza has boosted its ability to cater ... which provides manufacturing services to the category from facilities in Visp, Switzerland. The group is paying €100 million ($107 million) in cash ...